Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

First International Summit on Interventional Pharmacoeconomics

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Dec

Today In Oncology

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Lung Cancer Screening May Increase Long-Term Survival Rate

High Deductibles May Discourage Patients From Receiving Additional Testing After an Abnormal Mammogram

Study Finds Americans Have a Low Awareness of the Link Between Alcohol Use and Increased Cancer Risk

Does CBD Oil Improve Symptom Distress in Patients With Advanced Cancer Receiving Palliative Care

Incidence of Cervical Cancer in Women in the United States 2001 to 2019